Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLEX: Cetuximab + Chemo in NSCLC
NCT00148798Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Oct 2004
- Primary completion
- Jul 2007
- Modality
- Monoclonal Antibodies
- Countries
- 28
01
Overview
A Phase 3 trial of KL-140 in non-small cell lung cancer (NSCLC), sponsored by Merck KGaA. Started Oct 2004; status: completed.
02
Drugs
KL-140
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00148798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00148798.